Reel 02 / the evidence
NAD+ research: the mechanism, the aging axis, and the human trial record.
What controlled studies measured, organized by finding, with each route and precursor labeled and every quantitative claim cited.
Start here
This page reviews the NAD+ research record. NAD+ (a helper molecule cells use to turn food into energy) does two jobs: it ferries electrons to make energy, and it is spent as fuel by maintenance enzymes that repair DNA and regulate genes. As you age, the amount in your tissues drops. If you want the ground-floor definition first, the homepage covers what NAD+ is; this page goes deeper. The studies below ask two questions: why does it drop, and does raising it — usually with a precursor (a building block the body turns into NAD+, like NMN or NR) — change anything a trial can measure? The short answer: blood NAD+ goes up reliably; the downstream payoff is still being worked out [7].
Mechanism: redox carrier and consumed substrate
NAD+ has two distinct roles, and keeping them separate is the key to reading this literature. As a redox coenzyme, the NAD+/NADH couple shuttles electrons through glycolysis, the TCA cycle, and mitochondrial electron transport to drive ATP synthesis [5]. This role is catalytic — NAD+ cycles back and forth between its oxidized and reduced forms and is not used up.
The second role is. NAD+ is a consumed substrate for sirtuins (NAD+-dependent deacylase enzymes, SIRT1-7), PARPs (DNA-damage-response enzymes, chiefly PARP1), and CD38/CD157 (NAD-consuming ectoenzymes) [5]. Each cleaves NAD+ as part of its reaction, so these enzymes compete for a shared pool that must be continuously resynthesized [9]. A 2008 review positioned the NAD+/NADH and NADP+/NADPH couples as fundamental regulators of energy metabolism, calcium signaling, gene expression, and cell death [12]. A later review framed NAD+ as a node that translates a cell's energy status into metabolic adaptations through sirtuins and PARPs [10].
The CD38 aging axis
The clearest mechanistic explanation for why tissue NAD+ falls with age centers on CD38, an NAD-consuming ectoenzyme that rises with age and inflammation. In mice, CD38 deletion preserved NAD+ levels and SIRT3 activity, improved mitochondrial function, and protected against the age-related NAD+ decline — identifying CD38 as the principal driver of that decline through a SIRT3-dependent mechanism [2].
Mechanistically, CD38 is a major mammalian NAD+ glycohydrolase: it consumes intracellular NAD+ to generate the second messenger cyclic ADP-ribose, which limits how much NAD+ is left for PARPs, sirtuins, and other consumers [14]. As inflammatory and senescence signals accumulate with age, CD38 activity climbs, the NAD+ pool shrinks, and the maintenance enzymes that depend on it lose capacity [2][5]. This is the biological case for trying to replenish NAD+ — and it is largely a rodent and in-vitro case, which is why human translation is the open question [7].
What the research has measured in humans
Human evidence is strongest on one endpoint: blood NAD+ rises when you take a precursor. An 8-week NR trial in healthy overweight adults raised whole-blood NAD+ by 22%, 51%, and 142% at 100, 300, and 1000 mg/day respectively — dose-dependent, maintained throughout the study, with no flushing, no LDL-cholesterol elevation, and no significant adverse-event difference from placebo [4]. A multicenter, double-blind NMN trial (300-900 mg/day for 60 days) significantly raised blood NAD+ at days 30 and 60 across all dose groups versus placebo (p≤0.001), improved walking distance, and identified 600 mg/day as the optimal dose [3].
Functional results are more selective. Ten weeks of NMN at 250 mg/day improved muscle insulin sensitivity in prediabetic, postmenopausal women, measured by hyperinsulinemic-euglycemic clamp, with no change in body composition or HbA1c [8]. In mice, a hepatocyte mitochondrial NAD+ transporter (SLC25A47) sustained SIRT3 and AMPK activity, and its deletion increased liver lipid and promoted tumorigenesis — a mechanistic link between NAD+ transport and metabolic health, in rodents [11].
The synthesis that ties this together is the 2025 Nature Metabolism review: human trials have shown limited efficacy for hard clinical endpoints, age-related NAD+ decline has been consistently observed in only a limited number of human studies, and tissue NAD+ data remain sparse — the field needs more clinical studies, not more rodent extrapolation [7]. For the full citation list, see cited studies and references.